Cenegermin

塞奈吉明

Report date: 2026/05/13 20:02:10
First In Class

Base Information

Drug NameCenegermin
Drug Alias Name神经生长因子 - Anabasis/DompeCenegermin-bkbjNerve growth factor (Anabasis/Dompe)Recombinant human nerve growth factor(Anabasis/Dompe)Sentinel +[8] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionNeurons stimulantsNerve growth factor receptors agonists
TargetsNerve growth factor receptors
Therapy Area/IndicationsNeurotrophic KeratitisPersistent corneal epithelial defectDry Eye Syndromes +[11] 
Global Approved IndicationsKeratitis
Approved Indications in ChinaKeratitis
Original Approved Country/TerritoryEU
Original Approved Date2017/07/06
Country/TerritoryUnited StatesPolandItaly +[10] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesDompe Farmaceutici Spa
China Registration ClassN/A

Develop Information

Active CompaniesDompé farmaceutici SPADompe Farmaceutici SpaDompé Pharmaceutici Spa
Inactive CompaniesTufts Medical Center Inc
Active IndicationsPersistent corneal epithelial defectDry Eye SyndromesKeratitis +[5] 
Inactive IndicationsNeurotrophic KeratitisRetinitis PigmentosaCorneal Diseases +[6] 

Other Information

ATC CodeS01XA24
Related LinksN/A